National Cancer Plan

Peter Prinsley Excerpts

Thursday 5th February 2026 Commons Chamber

[Ashley Dalton]

The trust to which the right hon. Gentleman refers is the trust where I had my primary cancer treatment, so I am acutely aware of the challenges. We have set a really clear and simple ambition: to get cancer patients the timely care they need, and to meet all waiting time standards by the end of this Parliament. That means that by March 2029, 80% of patients will get a diagnosis or the all-clear within 28 days, and 85% of patients will start their treatment within 62 days of referral. Some people have asked me why the figure is not 100%. It is not possible to make it 100%, because not everybody’s cancer is simple or easy to identify, and sometimes it takes longer. We want to ensure that the only reason for delays beyond 62 days is the complexity or specifics of someone’s cancer, not the inability of a trust to meet the targets.

We are going to cut waiting times by giving trusts and cancer alliances detailed practical information and granular data on individual cancer types so that we can highlight real-time pathway insights through a federated data platform, and by streamlining the cancer metrics so that we can shine a light on unwarranted variation in care. We are providing information and best practice, thereby taking the best of the NHS to the rest of the NHS. We are linking up professionals and clinicians across the UK, so that they can share their best practice. Trusts can help and support each other to reach the targets.

[Peter Prinsley (Bury St Edmunds and Stowmarket) (Lab)]

What a brilliant plan, and I congratulate the Minister on bringing it to the House this afternoon. However, cancer trials need clinical academics, and we have a crisis in clinical academic recruitment, retention and funding. Does she agree that we must find ways to encourage young clinicians into academic and research roles?

[Ashley Dalton]

Yes, I do agree, and we are working on that. We are establishing the cancer trials accelerator programme to increase the speed, scale and reliability of cancer trials, and we will use the new health tech access programme to make it quicker. We will also be supporting the development, through the workforce plan, of all the clinicians required, including academics.